CYFRA21—1，CA125和LPA联合检测诊断卵巢恶性肿瘤

【目的】探讨肿瘤标志物联检与卵巢恶性肿瘤诊断的关系，提高卵巢恶性肿瘤的诊断率。【方法】采用电化学发光法检测CYFRA21-1和CA125，化学比色法测定LPA，将卵巢恶性肿瘤组的测定结果与正常女性时照组及卵巢良性肿瘤组进行比较。【结果】卵巢恶性肿瘤患者血清CYFRA21-1、CA125和血浆LPA水平及阳性率均明显高于正常女性对照组及卵巢良性肿瘤对照组（P〈0．05）；三项标志物组合检测的敏感性和诊断准确性均比单项检测高。【结论】联合检测血清中的CYFRA21—1、CA125和血浆LPA，可显著提高卵巢恶性肿瘤的诊断率。

Relationship Between Combined Measurement of Tumor Markers and the Diagnosis of Ovarian Malignant Tumor

Objective] To explore the relationship between the combined measurement of tumor markers and the diagnosis of ovarian malignant tumor so as to improve the diagnostic rate. Methods]Serum CYFRA21-1 and CA125 levels were detected by electrochemiluminescence method and plasma lysophosphatidic acid（LPA） level was detected by biochemical chromatometry. The results were compared among ovarian ma lignant tumor group, normal control group and ovarian benign tumor group. Results] The levels and the positive rates of serum CYFRA21-1, CA125 and plasma LPA in patients with ovarian malignant tumor were significantly higher than those in normal controls and patients with ovarian benign tumor（ P 〈0.05）. The diagnostic sensitivity and accuracy of combined detection of serum CYFRA21-1, CA125 and plasma LPA were higher than those of single assay. Conclusion] The combined measurement of serum CYFRA21-1, CA125 and plasma LPA can obviously improve the diagnostic rate of ovarian malignant tumor.